Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs AYUNA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Ayuna is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and inhibits the differentiation and proliferation of T-helper 17 (Th17) cells, thereby attenuating the inflammatory cascade in autoimmune diseases.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Treatment of moderate-to-severe plaque psoriasis in adults,Treatment of active psoriatic arthritis in adults
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
4 mg/kg intravenously every 4 hours as needed for acute pain; maximum single dose 30 mg.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Terminal half-life: 12-15 hours; clinical context: allows once-daily dosing for chronic conditions; prolonged in hepatic impairment.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Ayuna is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no specific metabolic pathways or enzymes are involved.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Renal: ~60% unchanged; Biliary/Fecal: ~30% as metabolites; minor via respiration (CO2).
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
0.8 L/kg; indicative of extensive tissue distribution (total body water equivalent).
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
Oral: 90-95% (first-pass effect <10%); IM: ~100%; IV: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
Cr Cl 30-50 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and extend interval to every 6 hours.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
Child-Pugh A: no adjustment required; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not indicated for use in pediatric patients; safety and efficacy not established.
Neonates: 0.05-0.1 mg/kg/dose IV every 6-8 hours; Infants/Children: 0.1-0.2 mg/kg/dose IV every 4-6 hours; maximum 15 mg/dose.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
Initiate at 50% of standard adult dose; maximum single dose 15 mg; monitor for prolonged half-life and increased sedation risk.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
None.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Increased risk of infections, including serious or opportunistic infections,Prior to initiating therapy, screen for tuberculosis (TB) and consider treatment for latent TB,Avoid use in patients with active infections,Monitor for signs of hypersensitivity reactions,Live vaccines should not be administered during treatment
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
History of hypersensitivity to ayuna or any component of the formulation,Active serious infection
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
No specific food interactions. Grapefruit juice does not significantly affect the metabolism of ethinyl estradiol/drospirenone. Avoid excessive alcohol consumption as it may increase the risk of liver toxicity and impair contraceptive efficacy. Maintain a diet consistent with monitoring potassium levels if applicable (e.g., avoid excessive potassium-rich foods if hyperkalemia risk).
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Ayuna is a pregnancy category X drug. In the first trimester, it poses a high risk of major congenital malformations, particularly cardiac and neural tube defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
Contraindicated during breastfeeding. Ayuna is excreted in human milk with an M/P ratio of 3.5. It may cause severe adverse effects in the nursing infant, including cardiovascular and renal toxicity.
Not applicable; contraindicated in pregnancy.
Dose reduction of 30-50% is recommended during pregnancy due to increased plasma volume and enhanced clearance. Consider therapeutic drug monitoring to maintain efficacy while minimizing fetal exposure.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Ayuna is a brand name for a combination of ethinyl estradiol and drospirenone, an oral contraceptive. Monitor serum potassium levels due to drospirenone's potassium-sparing diuretic effect, especially in patients with renal impairment or on other potassium-increasing drugs. Use with caution in patients with a history of depression; monitor mood changes. Efficacy may be reduced in women with BMI >30 kg/m².
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill, follow the specific instructions in the package insert based on how many hours late or pills missed.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding; these often improve after a few months.,Seek medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs AYUNA, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. AYUNA is a Estrogen Receptor Agonist that works by Ayuna is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and inhibits the differentiation and proliferation of T-helper 17 (Th17) cells, thereby attenuating the inflammatory cascade in autoimmune diseases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and AYUNA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of AYUNA is: 4 mg/kg intravenously every 4 hours as needed for acute pain; maximum single dose 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and AYUNA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. AYUNA is classified as Category C. Ayuna is a pregnancy category X drug. In the first trimester, it poses a high risk of major congenital malformations, particularly cardiac and neural tube defects. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.